Antitumor Molecular Mechanism of Trifluridine and Tipiracil Hydrochloride (TAS-102: TFTD)

Hiroyuki Kitao, Kazuaki Matsuoka, Makoto Iimori, Eriko Tokunaga, Hiroshi Saeki, Eiji Oki, Yuji Miyamoto, Hideo Baba, Yoshihiko Maehara

Research output: Contribution to journalReview article

Abstract

Treatment options for patients with metastatic colorectal cancer (mCRC), who are refractory to standard chemotherapy, are limited. In a global multicenter randomized double-blind phase III study (RECOURSE study), TAS-102 (TFTD) administration significantly improved overall survival rate with favorable safety profile in mCRC patients refractory to standard chemotherapy (HR=0.68, p<0.001). TFTD was approved initially in Japan in March 2014 and is currently under review by health authorities in the United States and Europe. TFTD is expected to play an important role in salvage-line treatment for patients with mCRC. In this review, we present the history of its clinical development and the experimental data that elucidate the underlying molecular mechanism of action of TFTD and its key component, trifluridine.

Original languageEnglish
Pages (from-to)8-14
Number of pages7
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume43
Issue number1
Publication statusPublished - Jan 1 2016

Fingerprint

Trifluridine
Colorectal Neoplasms
Drug Therapy
Salvage Therapy
Japan
Survival Rate
History
Safety
Health
TAS 102
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Antitumor Molecular Mechanism of Trifluridine and Tipiracil Hydrochloride (TAS-102 : TFTD). / Kitao, Hiroyuki; Matsuoka, Kazuaki; Iimori, Makoto; Tokunaga, Eriko; Saeki, Hiroshi; Oki, Eiji; Miyamoto, Yuji; Baba, Hideo; Maehara, Yoshihiko.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 43, No. 1, 01.01.2016, p. 8-14.

Research output: Contribution to journalReview article

Kitao, H, Matsuoka, K, Iimori, M, Tokunaga, E, Saeki, H, Oki, E, Miyamoto, Y, Baba, H & Maehara, Y 2016, 'Antitumor Molecular Mechanism of Trifluridine and Tipiracil Hydrochloride (TAS-102: TFTD)', Gan to kagaku ryoho. Cancer & chemotherapy, vol. 43, no. 1, pp. 8-14.
Kitao, Hiroyuki ; Matsuoka, Kazuaki ; Iimori, Makoto ; Tokunaga, Eriko ; Saeki, Hiroshi ; Oki, Eiji ; Miyamoto, Yuji ; Baba, Hideo ; Maehara, Yoshihiko. / Antitumor Molecular Mechanism of Trifluridine and Tipiracil Hydrochloride (TAS-102 : TFTD). In: Gan to kagaku ryoho. Cancer & chemotherapy. 2016 ; Vol. 43, No. 1. pp. 8-14.
@article{8638f81bb63f41988873eac40f0c8e5c,
title = "Antitumor Molecular Mechanism of Trifluridine and Tipiracil Hydrochloride (TAS-102: TFTD)",
abstract = "Treatment options for patients with metastatic colorectal cancer (mCRC), who are refractory to standard chemotherapy, are limited. In a global multicenter randomized double-blind phase III study (RECOURSE study), TAS-102 (TFTD) administration significantly improved overall survival rate with favorable safety profile in mCRC patients refractory to standard chemotherapy (HR=0.68, p<0.001). TFTD was approved initially in Japan in March 2014 and is currently under review by health authorities in the United States and Europe. TFTD is expected to play an important role in salvage-line treatment for patients with mCRC. In this review, we present the history of its clinical development and the experimental data that elucidate the underlying molecular mechanism of action of TFTD and its key component, trifluridine.",
author = "Hiroyuki Kitao and Kazuaki Matsuoka and Makoto Iimori and Eriko Tokunaga and Hiroshi Saeki and Eiji Oki and Yuji Miyamoto and Hideo Baba and Yoshihiko Maehara",
year = "2016",
month = "1",
day = "1",
language = "English",
volume = "43",
pages = "8--14",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "1",

}

TY - JOUR

T1 - Antitumor Molecular Mechanism of Trifluridine and Tipiracil Hydrochloride (TAS-102

T2 - TFTD)

AU - Kitao, Hiroyuki

AU - Matsuoka, Kazuaki

AU - Iimori, Makoto

AU - Tokunaga, Eriko

AU - Saeki, Hiroshi

AU - Oki, Eiji

AU - Miyamoto, Yuji

AU - Baba, Hideo

AU - Maehara, Yoshihiko

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Treatment options for patients with metastatic colorectal cancer (mCRC), who are refractory to standard chemotherapy, are limited. In a global multicenter randomized double-blind phase III study (RECOURSE study), TAS-102 (TFTD) administration significantly improved overall survival rate with favorable safety profile in mCRC patients refractory to standard chemotherapy (HR=0.68, p<0.001). TFTD was approved initially in Japan in March 2014 and is currently under review by health authorities in the United States and Europe. TFTD is expected to play an important role in salvage-line treatment for patients with mCRC. In this review, we present the history of its clinical development and the experimental data that elucidate the underlying molecular mechanism of action of TFTD and its key component, trifluridine.

AB - Treatment options for patients with metastatic colorectal cancer (mCRC), who are refractory to standard chemotherapy, are limited. In a global multicenter randomized double-blind phase III study (RECOURSE study), TAS-102 (TFTD) administration significantly improved overall survival rate with favorable safety profile in mCRC patients refractory to standard chemotherapy (HR=0.68, p<0.001). TFTD was approved initially in Japan in March 2014 and is currently under review by health authorities in the United States and Europe. TFTD is expected to play an important role in salvage-line treatment for patients with mCRC. In this review, we present the history of its clinical development and the experimental data that elucidate the underlying molecular mechanism of action of TFTD and its key component, trifluridine.

UR - http://www.scopus.com/inward/record.url?scp=84965093493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965093493&partnerID=8YFLogxK

M3 - Review article

C2 - 26809521

AN - SCOPUS:84965093493

VL - 43

SP - 8

EP - 14

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 1

ER -